All News

ACRmtg.jpg (keep)

ACR 2018 - Day 3 Report

d RheumNow

Highlights from Tuesday, day 3 of the ACR Annual meeting in Chicago, included the PEXIVAS Study, ACR Reproductive Health Draft Guidelines, and a Proof of concept study

Read Article
2019.jpeg

2019 Rheumatology Year in Review

d Jack Cush, MD

2019 was a year marked by major advances, hallmark research, and big news items affecting rheumatology.   Herein you will find our top 10 list, formulated by what I think rheumatologists should know and what will likely change their standards and practice in 2020 and beyond. 

Read Article
OA.DIPs_.PIPs_.jpg

ACR-Arthritis Foundation Treatment Guidelines for Osteoarthritis

d Jack Cush, MD

Today, the American College of Rheumatology (ACR), in partnership with the Arthritis Foundation (AF), released the 2019 ACR/AF Guideline for the Management of Osteoarthritis of the Hand, Hip and Knee.

Read Article
SI.Gr1_.jpg

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

d Jack Cush, MD

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA).

Read Article
RN.podcast.resized.jpg

RheumNow Podcast - 2019 Rheumatology Year in Review

d Jack Cush, MD

Dr. Jack Cush reviews highlights from 2019 on RheumNow.com. Topics covered in this annual review include: superheroes lost; venous thromboembolic events and JAKs; free medical tuition; women in rheumatology; 52 new drug approvals in 2019 and 330 drugs with a 2020 price hike; scleroderma disappointments; novel new treatments and newer tests; the boom of Shingrix; RheumNow.Live - and more.

Read Article
Dr. Heidi Jacobi #UTSW says Raynauds, puffy digits and a +ANA should raise suspicion of systemic sclerosis. Also Carol tunnel syndrome may be a presenting feature

Dr. John Cush RheumNow ( View Tweet)

Dr. Heidi Jacobi #UTSW lecturing on scleromyxedema often with "pebble like" lesions that during it from scleroderma https://t.co/5odVXrglyT
Dr. John Cush RheumNow ( View Tweet)
#UTSW Rheumatology grand rounds with Dr Heidi Jacobi . Serologic and lab findings in patients with MOPHEA https://t.co/d619QnYrZ9
Dr. John Cush RheumNow ( View Tweet)
Toscana is an arbovirus transmitted by sand flies in the Mediterranean. May fever, neuroinvasive infections & is an important cause of meningitis and encephalitis. May also cause Guillain-Barré, myositis, fasciitis, polymyeloradiculopathy, deafness, https://t.co/9X4OwAqRF9

Links:

Dr. John Cush RheumNow ( View Tweet)

Misuse and abuse of Gabapentin in US? Between 2003-2016 there were 260 million gabapentinoid visits. Annual use nearly quadrupled from 2003 to 2016 (mostly PCPs 46%). Nearly half w/ concurrent opioids (32.9%) or benzodiazepines (15.3%). https://t.co/Wnja1mkDQo

Links:

Dr. John Cush RheumNow ( View Tweet)

Systematic literature of biologic Rx of dactylitis & enthesitis in Psoriatic arthritis. 18 trials, 6981 patients showed that TNF inhib & ustekinumab, secukinumab, ixekizumab were 2-3 fold significantly better than PBO at resolution of dactylitis by Wk 24. https://t.co/HlQcw5cXsN

Links:

Dr. John Cush RheumNow ( View Tweet)

301 fibromyalgia #FM pts randomized to receive active‐TENS or placebo‐TENS or no‐TENS to use at home 2h/day for 4 wks. Active TENS had greater reduction in pain & fatigue vs placeboAND better global improvement (70% vs. 31%, p<0.0001) https://t.co/AH84DxlTo3

Links:

Dr. John Cush RheumNow ( View Tweet)

CORRONA registry 880 RA pts developed a solid cancer. 42% taking bDMARD/tsDMARD; 5% switched biologics w/in 36 mos & 10% started a new biologic- w/ most changing to a TNFi (53%). ACR guidelines say to Rx regardless of solid tumor https://t.co/pPgnYNdT7Q

Links:

Dr. John Cush RheumNow ( View Tweet)

high-dose trivalent inactivated influenza vaccine (HD-TIV) was studied in 696 RA patients compared to standard-dose quadrivalent flu vaccine - Seroconversion was 3 fold higher w/ HD-TIV, no differences in side effects and no increase in RA flares https://t.co/1JBs95vGSA

Links:

Dr. John Cush RheumNow ( View Tweet)

Claims data from RA patients (n = 12,182), shows that screening for hyperlipidemia was suboptimal (compared to Diabetes pts), Those seeing a PCP and Rheum were 36% more likely to be screened. https://t.co/j661loTDGk

Links:

Dr. John Cush RheumNow ( View Tweet)

From the 9/11 World Trade Center registry, 118 persons found w/ a CTD (RA=71, Sjӧgrens 22, SLE 20, myositis 9,MCTD 7, PSS 4. Responders w/ intense dust cloud exposure had 2 fold CTD risk & Community members w/ PTSD had 3‐fold risk. https://t.co/07GhloezNA

Links:

Dr. John Cush RheumNow ( View Tweet)

2019 YEAR IN REVIEW Podcast is up! Superheros, women, New Drugs, Novel Approaches, Failed drugs, MTX, Who's killing medicine & low dose pred Watch here>> https://t.co/sYb3KvivJK or Podcast Listen on iTunes https://t.co/FlPe6BQ3BW or Soundcloud >> https://t.co/FlPe6BQ3BW

Links:

Dr. John Cush RheumNow ( View Tweet)

2019 YEAR IN REVIEW Podcast is up! Superheros, women, New Drugs, Novel Approaches, Failed drugs, MTX, Who's killing medicine & low dose pred Watch here>> https://t.co/sYb3KvivJK or Podcast Listen on iTunes https://t.co/FlPe6BQ3BW or Soundcloud >> https://t.co/FlPe6BQ3BW

Links:

Dr. John Cush RheumNow ( View Tweet)

Check out my 2019 Rheumatology Year in Review - now on RheumNow https://t.co/sYb3KvivJK

Links:

Dr. John Cush RheumNow ( View Tweet)

Rates of "indeterminate" results on quantiferon-IT assays were found to be significantly higher in systemic vasculitis (21%) than nonvasculitis pts and controls (7-7.5%). Indeterminate predictors were Syst vasculitis (OR 9.64), high NLR (OR 1.70). https://t.co/roZINmKgZ1

Links:

Dr. John Cush RheumNow ( View Tweet)

×